{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:03:11Z","timestamp":1792468991161,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40265-022-01794-0","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T05:02:55Z","timestamp":1666674175000},"page":"1541-1548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"issue":"5","key":"1794_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41571-022-00606-4","volume":"19","author":"LR Klug","year":"2022","unstructured":"Klug LR, Khosroyani HM, Kent JD, et al. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol. 2022;19(5):328\u201341.","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"1794_CR2","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/cncr.33630","volume":"127","author":"SR Patel","year":"2021","unstructured":"Patel SR, Reichardt P. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. Cancer. 2021;127(13):2187\u201395.","journal-title":"Cancer"},{"issue":"2","key":"1794_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00428-017-2285-x","volume":"472","author":"AJ Verschoor","year":"2018","unstructured":"Verschoor AJ, Bovee J, Overbeek LIH, et al. The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study. Virchows Arch. 2018;472(2):221\u20139.","journal-title":"Virchows Arch"},{"issue":"23","key":"1794_CR4","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357\u201364.","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"1794_CR5","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80599-8","volume":"38","author":"PW Manley","year":"2002","unstructured":"Manley PW, Cowan-Jacob SW, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer. 2002;38(Suppl 5):S19-27.","journal-title":"Eur J Cancer"},{"issue":"29","key":"1794_CR6","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","volume":"24","author":"MC Heinrich","year":"2006","unstructured":"Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24(29):4764\u201374.","journal-title":"J Clin Oncol"},{"key":"1794_CR7","unstructured":"US FDA. Qinlock\u00ae (ripretinib) tablets: US prescribing information. 2021. https:\/\/www.qinlockhcp.com\/. Accessed 28 Sep 2022."},{"key":"1794_CR8","unstructured":"European Medicines Agency. QINLOCK 50 mg tablets: summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 28 Sep 2022."},{"issue":"5","key":"1794_CR9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","volume":"35","author":"BD Smith","year":"2019","unstructured":"Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738-51.e9.","journal-title":"Cancer Cell"},{"issue":"28","key":"1794_CR10","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1200\/JCO.20.00522","volume":"38","author":"F Janku","year":"2020","unstructured":"Janku F, Abdul Razak AR, Chi P, et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib. J Clin Oncol. 2020;38(28):3294\u2013303.","journal-title":"J Clin Oncol"},{"key":"1794_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1110","author":"X Li","year":"2022","unstructured":"Li X, Shelton MJ, Wang J, et al. Effects of CYP3A inhibition, CYP3A induction, and gastric acid reduction on the pharmacokinetics of ripretinib, a switch control KIT tyrosine kinase inhibitor. Clin Pharmacol Drug Dev. 2022. https:\/\/doi.org\/10.1002\/cpdd.1110.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"1794_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"J-Y Blay","year":"2020","unstructured":"Blay J-Y, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923\u201334.","journal-title":"Lancet Oncol"},{"issue":"23","key":"1794_CR13","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1158\/1078-0432.CCR-21-1864","volume":"27","author":"S Bauer","year":"2021","unstructured":"Bauer S, Heinrich MC, George S, et al. Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogeneous KIT\/PDGFRA mutations in the phase III INVICTUS study. Clin Cancer Res. 2021;27(23):6333\u201342.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1794_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"9863","key":"1794_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295\u2013302.","journal-title":"Lancet"},{"issue":"Suppl 5","key":"1794_CR16","doi-asserted-by":"publisher","first-page":"S1120","DOI":"10.1016\/j.annonc.2021.08.870","volume":"32","author":"M von Mehren","year":"2021","unstructured":"von Mehren M, Heinrich MC, George S, et al. Ripretinib as \u2265 4th-line treatment in patients with advanced gastrointestinal stromal tumor: long-term update from the phase III INVICTUS study [abstract no. 1540P and poster]. Ann Oncol. 2021;32(Suppl 5):S1120\u20131.","journal-title":"Ann Oncol"},{"issue":"11","key":"1794_CR17","doi-asserted-by":"publisher","first-page":"e2053","DOI":"10.1002\/onco.13917","volume":"26","author":"JR Zalcberg","year":"2021","unstructured":"Zalcberg JR, Heinrich MC, George S, et al. Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: an analysis of the INVICTUS study. Oncologist. 2021;26(11):e2053\u201360.","journal-title":"Oncologist"},{"key":"1794_CR18","doi-asserted-by":"publisher","first-page":"JCO2200294","DOI":"10.1200\/JCO.22.00294","volume":"2022","author":"S Bauer","year":"2022","unstructured":"Bauer S, Jones RL, Blay JY, et al. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): a randomized, open-label, phase III trial. J Clin Oncol. 2022;2022:JCO2200294.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1794_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491\u2013500.","journal-title":"Lancet Oncol"},{"issue":"Suppl 3","key":"1794_CR20","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.annonc.2021.05.162","volume":"32","author":"A Patel","year":"2021","unstructured":"Patel A, George S, Janku F, et al. Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib [abstract no. P-107 and poster]. Ann Oncol. 2021;32(Suppl 3):S134\u20135.","journal-title":"Ann Oncol"},{"issue":"1","key":"1794_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","volume":"118","author":"MH Chen","year":"2008","unstructured":"Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118(1):84\u201395.","journal-title":"Circulation"},{"issue":"16 Suppl","key":"1794_CR22","doi-asserted-by":"publisher","first-page":"e16031","DOI":"10.1200\/JCO.2022.40.16_suppl.e16031","volume":"40","author":"X Li","year":"2022","unstructured":"Li X, Psoinos CM, Shelton MJ, et al. Effect of hepatic impairment on the pharmacokinetics of ripretinib [abstract no. e16031]. J Clin Oncol. 2022;40(16 Suppl):e16031.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1794_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO\u2013EURACAN\u2013GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20\u201333.","journal-title":"Ann Oncol"},{"key":"1794_CR24","unstructured":"National Comprehensive Cancer Network. Gastroinestinal stromal tumors (GISTs): NCCN guidelines version 2.2022. 2022. https:\/\/www.nccn.org\/. Accessed 28 Sep 2022."},{"key":"1794_CR25","unstructured":"Taiho Pharmaceutical Co. Taiho pharmaceutical obtains approval to manufacture and market HSP90 inhibitor Jeselhy\u00ae tablets 40 mg (pimitespib) for gastrointestinal stromal tumor (GIST) [media release]. 20 June 2022. https:\/\/www.taiho.co.jp\/."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01794-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T18:38:55Z","timestamp":1668191935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01794-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":25,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1794"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01794-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"29 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S. Fung and M. Shirley are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}